• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Dow Falls Over 150 Points; Sohu Posts Q1 Loss

    5/20/24 2:31:29 PM ET
    $AKTS
    $JAGX
    $MIRA
    $MMV
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $AKTS alert in real time by email

    U.S. stocks traded mixed toward the end of trading, with the Dow Jones index falling more than 150 points on Monday.

    The Dow traded down 0.43% to 39,831.18 while the NASDAQ rose 0.53% to 16,775.01. The S&P 500 also rose, gaining, 0.09% to 5,307.88.

    Check This Out: Top 3 Financial Stocks That Are Set To Fly This Quarter

    Leading and Lagging Sectors

    Information technology shares rose by 1.3% on Monday.

    In trading on Monday, financial shares fell by 0.7%.

    Top Headline

    Shares of Sohu.com Limited (NASDAQ:SOHU) edged higher on Monday after the company reported its results for the fiscal first quarter of 2024.

    Sohu.com reported a revenue decline of 14% year-over-year to $139.4 million for the fiscal first quarter of 2024. Revenue was down by 1% Q/Q. The Chinese internet company’s adjusted loss per ADS was 65 cents, missing the analyst consensus loss estimate of 49 cents.

    Equities Trading UP
                           

    • NKGen Biotech, Inc. (NASDAQ:NKGN) shares shot up 55% to $1.7350 after the company’s SNK01 NK Cell Therapy was cleared to begin a Phase 2 trial in Alzheimer’s disease.
    • Shares of MIRA Pharmaceuticals, Inc. (NASDAQ:MIRA) got a boost, surging 36% to $0.8990 after the company said it has advanced new preclinical studies using Ketamir-2 towards clinical development.
    • MultiMetaVerse Holdings Limited (NASDAQ:MMV) shares were also up, gaining 141% to $1.4914. MultiMetaVerse Holdings signed a non-binding term sheet to acquire 100% of Bowong Technology (Shenzhen) Co., Ltd. and its subsidiaries.

    Equities Trading DOWN

    • Virios Therapeutics, Inc. (NASDAQ:VIRI) shares dropped 43% to $0.20 after the company priced a $1.7 million public offering of 8.5 million shares of common stock at $0.20 per share.
    • Shares of Akoustis Technologies, Inc. (NASDAQ:AKTS) were down 56% to $0.1560 after Qorvo won a jury verdict against the company in a trade secret misappropriation and patent infringement case.
    • Jaguar Health, Inc (NASDAQ:JAGX) was down, falling 36% to $0.1649 after the company announced a 1-for-60 reverse stock split.

    Also Check This Out: This Analyst With 85% Accuracy Rate Sees Around 8% Upside In NVIDIA – Here Are 5 Stock Picks For Last Week From Wall Street’s Most Accurate Analysts

    Commodities

    In commodity news, oil traded down 0.5% to $79.65 while gold traded up 0.9% at $2,439.90.

    Silver traded up 3.6% to $32.37 on Monday, while copper rose 1.1% to $5.0545.

    Euro zone

    European shares were higher today. The eurozone's STOXX 600 gained 0.18%, Germany's DAX rose 0.35% and France's CAC 40 climbed 0.35%. Spain's IBEX 35 Index rose 0.10%, while London's FTSE 100 rose 0.05%.

    Spain’s consumer confidence indicator climbed to 84.5 in April compared to 82.5 in March. The construction output in Italy rose by 3.8% year-over-year in March.

    Asia Pacific Markets

    Asian markets closed higher on Monday, with Japan's Nikkei gaining 0.73%, China's Composite Index climbing 0.54%, Hong Kong's Hang Seng Index gaining 0.42% and India's S&P BSE Sensex gaining 0.46%.

    Hong Kong's unemployment rate came in unchanged at 3% in the three months ending April 2024. Malaysia’s trade surplus shrank to MYR 7.7 billion in April from MYR 12.6 billion in the year-ago month. The People’s Bank of China held key lending rates at the recent fixing.

    Economics

    No major economic reports will be released today.

    Now Read This: Insiders Buying Sempra And 2 Other Stocks

    Get the next $AKTS alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $AKTS
    $JAGX
    $MIRA
    $MMV

    CompanyDatePrice TargetRatingAnalyst
    Aktis Oncology Inc.
    $AKTS
    2/3/2026$30.00Overweight
    Analyst
    Aktis Oncology Inc.
    $AKTS
    2/3/2026$34.00Buy
    BofA Securities
    Aktis Oncology Inc.
    $AKTS
    2/3/2026$31.00Outperform
    Leerink Partners
    Aktis Oncology Inc.
    $AKTS
    2/3/2026Buy
    TD Cowen
    Aktis Oncology Inc.
    $AKTS
    1/4/2024$2.00 → $1.00Overweight → Neutral
    Piper Sandler
    Aktis Oncology Inc.
    $AKTS
    9/6/2023$9.25 → $1.75Buy → Neutral
    B. Riley Securities
    Aktis Oncology Inc.
    $AKTS
    1/24/2023$9.25Buy
    B. Riley Securities
    Virios Therapeutics Inc.
    $VIRI
    12/15/2021$12.00Buy
    HC Wainwright & Co.
    More analyst ratings

    $AKTS
    $JAGX
    $MIRA
    $MMV
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    SOHU.COM REPORTS FOURTH QUARTER AND FISCAL YEAR 2025 UNAUDITED FINANCIAL RESULTS

    BEIJING, Feb. 9, 2026 /PRNewswire/ -- Sohu.com Limited (NASDAQ:SOHU) ("Sohu" or the "Company"), a leading Chinese online media platform and game business group, today reported unaudited financial results for the fourth quarter and fiscal year ended December 31, 2025. Fourth Quarter Highlights Total revenues were US$142 million, up 6% year-over-year and down 21% quarter-over-quarter.Marketing services revenues were US$17 million, down 10% year-over-year and up 25% quarter-over-quarter.Online game revenues were US$120 million, up 10% year-over-year and down 26% quarter-over-quar

    2/9/26 12:00:00 AM ET
    $SOHU
    EDP Services
    Technology

    Sohu.com to Report Fourth Quarter and Fiscal Year 2025 Financial Results on February 9, 2026

    BEIJING, Jan. 30, 2026 /PRNewswire/ -- Sohu.com Limited (NASDAQ:SOHU), a leading Chinese online media platform and game business group, will report its fourth quarter and fiscal year 2025 unaudited financial results on Monday, February 9, 2026, before U.S. market hours. Sohu's management team will host a conference call on the same day at 7:30 a.m. U.S. Eastern Time, February 9, 2026 (8:30 p.m. Beijing/Hong Kong time, February 9, 2026) following the quarterly results announcement. Conference Call Preregistration Participants can register for the conference call by click here,

    1/30/26 12:00:00 AM ET
    $SOHU
    EDP Services
    Technology

    NKGen Biotech Names Leading Dementia Expert Bruce L. Miller, M.D. to Scientific Advisory Board

    SANTA ANA, Calif., Jan. 22, 2026 (GLOBE NEWSWIRE) -- NKGen Biotech, Inc. (OTC:NKGN) ("NKGen" or the "Company"), a clinical-stage biotechnology company focused on the development and commercialization of innovative autologous and allogeneic natural killer ("NK") cell therapeutics, today announced the appointment of Bruce L. Miller, M.D. to its Scientific Advisory Board. Dr. Miller is internationally recognized for his leadership in Alzheimer's disease ("AD"), frontotemporal dementia ("FTD"), and other neurocognitive disorders, and brings extensive scientific and clinical expertise to the Company. Dr. Miller is the A.W. and Mary Margaret Clausen Distinguished Professor in Neurology at the U

    1/22/26 8:05:00 AM ET
    $NKGN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $AKTS
    $JAGX
    $MIRA
    $MMV
    SEC Filings

    View All

    SEC Form 6-K filed by Sohu.com Limited

    6-K - Sohu.com Ltd (0001734107) (Filer)

    2/9/26 6:01:17 AM ET
    $SOHU
    EDP Services
    Technology

    MIRA Pharmaceuticals Inc. filed SEC Form 8-K: Other Events

    8-K - MIRA PHARMACEUTICALS, INC. (0001904286) (Filer)

    2/2/26 4:01:44 PM ET
    $MIRA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Jaguar Health Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Financial Statements and Exhibits

    8-K - Jaguar Health, Inc. (0001585608) (Filer)

    1/23/26 4:15:29 PM ET
    $JAGX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AKTS
    $JAGX
    $MIRA
    $MMV
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Analyst initiated coverage on Aktis Oncology with a new price target

    Analyst initiated coverage of Aktis Oncology with a rating of Overweight and set a new price target of $30.00

    2/3/26 6:54:43 AM ET
    $AKTS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    BofA Securities initiated coverage on Aktis Oncology with a new price target

    BofA Securities initiated coverage of Aktis Oncology with a rating of Buy and set a new price target of $34.00

    2/3/26 6:54:33 AM ET
    $AKTS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Leerink Partners initiated coverage on Aktis Oncology with a new price target

    Leerink Partners initiated coverage of Aktis Oncology with a rating of Outperform and set a new price target of $31.00

    2/3/26 6:54:33 AM ET
    $AKTS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AKTS
    $JAGX
    $MIRA
    $MMV
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Officer King Steven R. was granted 11,740 shares, increasing direct ownership by 8,097% to 11,885 units (SEC Form 4)

    4 - Jaguar Health, Inc. (0001585608) (Issuer)

    1/21/26 4:30:46 PM ET
    $JAGX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Officer Conte Lisa A was granted 28,592 shares, increasing direct ownership by 4,293% to 29,258 units (SEC Form 4)

    4 - Jaguar Health, Inc. (0001585608) (Issuer)

    1/21/26 4:30:40 PM ET
    $JAGX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Officer Wolin Jonathan S. was granted 11,740 shares, increasing direct ownership by 5,929% to 11,938 units (SEC Form 4)

    4 - Jaguar Health, Inc. (0001585608) (Issuer)

    1/21/26 4:30:27 PM ET
    $JAGX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AKTS
    $JAGX
    $MIRA
    $MMV
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Foley Todd converted options into 4,002,533 shares and bought $4,191,660 worth of shares (232,870 units at $18.00) (SEC Form 4)

    4 - Aktis Oncology, Inc. (0002035832) (Issuer)

    1/14/26 6:20:21 PM ET
    $AKTS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Large owner Mpm Bioventures 2018, L.P. converted options into 8,805,578 shares and bought $20,029,986 worth of shares (1,112,777 units at $18.00) (SEC Form 4)

    4 - Aktis Oncology, Inc. (0002035832) (Issuer)

    1/14/26 6:19:26 PM ET
    $AKTS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Large owner Gadicke Ansbert converted options into 8,805,578 shares and bought $20,029,986 worth of shares (1,112,777 units at $18.00) (SEC Form 4)

    4 - Aktis Oncology, Inc. (0002035832) (Issuer)

    1/14/26 6:17:54 PM ET
    $AKTS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AKTS
    $JAGX
    $MIRA
    $MMV
    Leadership Updates

    Live Leadership Updates

    View All

    NKGen Biotech Names Leading Dementia Expert Bruce L. Miller, M.D. to Scientific Advisory Board

    SANTA ANA, Calif., Jan. 22, 2026 (GLOBE NEWSWIRE) -- NKGen Biotech, Inc. (OTC:NKGN) ("NKGen" or the "Company"), a clinical-stage biotechnology company focused on the development and commercialization of innovative autologous and allogeneic natural killer ("NK") cell therapeutics, today announced the appointment of Bruce L. Miller, M.D. to its Scientific Advisory Board. Dr. Miller is internationally recognized for his leadership in Alzheimer's disease ("AD"), frontotemporal dementia ("FTD"), and other neurocognitive disorders, and brings extensive scientific and clinical expertise to the Company. Dr. Miller is the A.W. and Mary Margaret Clausen Distinguished Professor in Neurology at the U

    1/22/26 8:05:00 AM ET
    $NKGN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    NKGen Biotech, Inc. Issues Statement on Recent Board Appointments at Majority-Owned Korean Affiliate NKGen Korea Co., Ltd.

    SANTA ANA, Calif., Dec. 03, 2025 (GLOBE NEWSWIRE) -- NKGen Biotech, Inc. (OTC:NKGN) ("NKGen" or the "Company"), a clinical-stage biotechnology company focused on the development and commercialization of innovative autologous and allogeneic natural killer ("NK") cell therapeutics and the majority owner of NKGen Biotech Korea Co., Ltd. ("NKGen Korea"), today issued the following statement regarding recent changes to the NKGen Korea Board of Directors (the "NKGen Korea Board"). NKGen Korea, formerly NKMax Co., Ltd., recently completed a shareholder-approved name change on November 21, 2025. On this date, NKGen Korea also announced through its official KOSDAQ disclosures the appointment of th

    12/3/25 8:05:00 AM ET
    $NKGN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    NKGen Appoints Dr. Anita Fletcher as National Principal Investigator for Phase 2a Troculeucel Trial Evaluating Moderate Alzheimer's Disease with AdventHealth Orlando as First East Coast Site

    SANTA ANA, Calif., Feb. 19, 2025 (GLOBE NEWSWIRE) -- NKGen Biotech, Inc. (NASDAQ:NKGN) ("NKGen" or the "Company"), a clinical-stage biotechnology company focused on the development and commercialization of innovative autologous and allogeneic natural killer ("NK") cell therapeutics, today announced that Anita Fletcher, M.D. has been appointed as the National Principal Investigator ("PI") for its Phase 2a clinical trial of troculeucel, expanded enhanced autologous NK cell therapy, for the treatment of moderate Alzheimer's disease (NCT06189963). In addition to Dr. Fletcher's appointment as National PI, NKGen is pleased to announce AdventHealth Research Institute, Neuroscience Research in Orl

    2/19/25 8:00:00 AM ET
    $NKGN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $AKTS
    $JAGX
    $MIRA
    $MMV
    Financials

    Live finance-specific insights

    View All

    SOHU.COM REPORTS FOURTH QUARTER AND FISCAL YEAR 2025 UNAUDITED FINANCIAL RESULTS

    BEIJING, Feb. 9, 2026 /PRNewswire/ -- Sohu.com Limited (NASDAQ:SOHU) ("Sohu" or the "Company"), a leading Chinese online media platform and game business group, today reported unaudited financial results for the fourth quarter and fiscal year ended December 31, 2025. Fourth Quarter Highlights Total revenues were US$142 million, up 6% year-over-year and down 21% quarter-over-quarter.Marketing services revenues were US$17 million, down 10% year-over-year and up 25% quarter-over-quarter.Online game revenues were US$120 million, up 10% year-over-year and down 26% quarter-over-quar

    2/9/26 12:00:00 AM ET
    $SOHU
    EDP Services
    Technology

    Sohu.com to Report Fourth Quarter and Fiscal Year 2025 Financial Results on February 9, 2026

    BEIJING, Jan. 30, 2026 /PRNewswire/ -- Sohu.com Limited (NASDAQ:SOHU), a leading Chinese online media platform and game business group, will report its fourth quarter and fiscal year 2025 unaudited financial results on Monday, February 9, 2026, before U.S. market hours. Sohu's management team will host a conference call on the same day at 7:30 a.m. U.S. Eastern Time, February 9, 2026 (8:30 p.m. Beijing/Hong Kong time, February 9, 2026) following the quarterly results announcement. Conference Call Preregistration Participants can register for the conference call by click here,

    1/30/26 12:00:00 AM ET
    $SOHU
    EDP Services
    Technology

    SOHU.COM REPORTS THIRD QUARTER 2025 UNAUDITED FINANCIAL RESULTS

    BEIJING, Nov. 17, 2025 /PRNewswire/ -- Sohu.com Limited (NASDAQ:SOHU) ("Sohu" or the "Company"), a leading Chinese online media platform and game business group, today reported unaudited financial results for the third quarter ended September 30, 2025. Third Quarter Highlights Total revenues were US$180 million, up 19% year-over-year and 43% quarter-over-quarter.Marketing services revenues were US$14 million, down 27% year-over-year and 13% quarter-over-quarter.Online game revenues were US$162 million, up 27% year-over-year and 53% quarter-over-quarter.GAAP net income attribut

    11/17/25 12:00:00 AM ET
    $SOHU
    EDP Services
    Technology

    $AKTS
    $JAGX
    $MIRA
    $MMV
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Akoustis Technologies Inc.

    SC 13G/A - Akoustis Technologies, Inc. (0001584754) (Subject)

    11/12/24 1:34:05 PM ET
    $AKTS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G filed by Akoustis Technologies Inc.

    SC 13G - Akoustis Technologies, Inc. (0001584754) (Subject)

    11/4/24 11:00:32 AM ET
    $AKTS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13D filed by Virios Therapeutics Inc.

    SC 13D - Virios Therapeutics, Inc. (0001818844) (Subject)

    10/15/24 4:19:38 PM ET
    $VIRI
    Biotechnology: Pharmaceutical Preparations
    Health Care